Objectives: To examine the tracking of abdominal fat distribution from the age of 7 to 15 years and to estimate the risk of abdominal obesity at 15 based on the occurrence of abdominal obesity at the ages 7-14 years in boys and girls.
Methods: The analysis was performed on 8-year longitudinal measurements of 315 boys and 198 girls from Cracow, Poland. The stability of waist circumference (WC) and waist-to-height ratio (WHtR) got assessed by inter-age correlations. The degree of abdominal fatness continuation level was evaluated applying contingency tables with the χ² test based on quartiles of WC and WHtR distribution. The risk of abdominal obesity at 15 was estimated using odds ratio (OR) and 95% confidence interval.
Results: Inter-age correlations between the 7(th) and 15(th) years were 0.73 and 0.67 in boys and 0.48 and 0.48 in girls for WC and WHtR, respectively. More than 51% girls and 62% boys with abdominal fat distribution at 7 remained in the same category in adolescence period, while only 2% of them moved to the thin category at 15. The risk of abdominal obesity (WHtR) was highest in boys and girls with abdominal obesity at 7 (OR = 5.46 and OR = 6.19, respectively) and, additionally, in girls at 12 (OR = 5.59).
Conclusion: The risk of abdominal obesity was indicated already at 7 in boys and girls. Continuation of the abdominal fat distribution confirmed in about 60% acknowledges that the type of fat distribution seems to be determined as early as in the 7-year-olds.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ajhb.22204 | DOI Listing |
Cancer Epidemiol Biomarkers Prev
January 2025
University of Alabama at Birmingham, Birmingham, AL, United States.
Background: The association between skeletal muscle and adipose tissue (body composition) and early response using positron emission tomography (PET) in pediatric Hodgkin lymphoma (HL) remains unstudied.
Methods: Patients enrolled on Children's Oncology Group studies AHOD0031 (intermediate-risk HL) and AHOD0831 (high-risk HL) with digital abdominal computed tomography (CT) scans at diagnosis and PET scans after 2 cycles (PET2) were included. Two consecutive slices at the third lumbar vertebra were identified and skeletal muscle index (SMI, in cm2/m2) and total adipose tissue index (TATI, in cm2/m2) were calculated using sliceOmatic (Magog, Canada) and height at diagnosis.
Endocr Metab Immune Disord Drug Targets
January 2025
Pharmacy Department, Tishk International University, Erbil, Kurdistan Region, Iraq.
Sedentary lifestyles and prolonged physical inactivity are often linked to poor mental and physical health as well as an increased risk of a number of chronic illnesses, including cancer, obesity, type 2 diabetes, and cardiovascular problems. Metabolic Syndrome (MetS), as the new disease, has emerged as the world's leading cause of illness. Despite having its roots in the West, this issue has now completely globalized due to the development of the Western way of life throughout the world.
View Article and Find Full Text PDFDiabetes Metab Syndr
November 2024
National Diabetes Obesity and Cholesterol Foundation (N-DOC), New Delhi, India; Diabetes Foundation India, New Delhi, India.
Aim: The prevailing guidelines for obesity in Asian Indians, published in 2009, relied solely on body mass index (BMI) criteria. Recognizing the limitations of BMI in accurately diagnosing obesity and the emergence of new research revealing the association between generalized and abdominal adiposity in Asian Indians and early-onset co-morbid diseases, a comprehensive redefinition was needed.
Method: In a Delphi process focused on obesity in India, experts were invited via email to participate in five rounds.
J Infect Dis
January 2025
Department of Internal Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Background: In people with HIV (PWH) who are virally suppressed (VS) on antiretroviral therapy (ART), abdominal obesity (AO) is linked to neurocognitive impairment (NCI), potentially due to visceral adiposity, inflammation, and reduced insulin-like growth factor 1 (IGF-1). Tesamorelin, a growth hormone-releasing hormone, reduces AO and increases IGF-1, suggesting it might mitigate NCI in VS PWH.
Methods: This 6-month, Phase II randomized, open-label clinical trial compared Tesamorelin versus standard-of-care (SOC) for NCI in abdominally obese PWH.
Cureus
December 2024
Department of General Surgery, Jordanian Royal Medical Services, Amman, JOR.
Background: Obesity is a growing global health issue, with a prevalence rate of 28.8% in Jordan. Bariatric surgery is the most effective treatment for morbid obesity, yet complications such as postoperative bleeding and leakage remain significant concerns.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!